Of note, although increments in sFasL serum levels have been observed in numerous pulmonary pathologies, it was shown to decrease in pneumonic effusion, acute respiratory distress syndrome and lung cancer [4,6,54,68]. This evidence concerns the gene FASLG and lung cancer.